115 related articles for article (PubMed ID: 30327151)
1. Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures.
Deng H; Liu C; Zhang G; Wang X; Liu Y
Pathol Res Pract; 2018 Dec; 214(12):2103-2105. PubMed ID: 30327151
[TBL] [Abstract][Full Text] [Related]
2. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
[TBL] [Abstract][Full Text] [Related]
3. TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.
Jiang B; Hu L; Dong D; Guo Z; Wei W; Wang C; Shao W; Ma T; Chen Y; Li Q; Hu W
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10041-10052. PubMed ID: 37261522
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients.
Schluckebier L; Caetano R; Garay OU; Montenegro GT; Custodio M; Aran V; Gil Ferreira C
BMC Cancer; 2020 Sep; 20(1):875. PubMed ID: 32928143
[TBL] [Abstract][Full Text] [Related]
5. Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
Sakamoto T; Matsubara T; Takahama T; Yokoyama T; Nakamura A; Tokito T; Okamoto T; Akamatsu H; Oki M; Sato Y; Tobino K; Ikeda S; Mori M; Mimura C; Maeno K; Miura S; Harada T; Nishimura K; Hiraoka M; Kenmotsu H; Fujimoto J; Shimokawa M; Yamamoto N; Nakagawa K
JAMA Netw Open; 2023 Dec; 6(12):e2347700. PubMed ID: 38100106
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients.
Zhang X; Jiang Y; Yu H; Xia H; Wang X
World J Surg Oncol; 2020 Jul; 18(1):172. PubMed ID: 32677962
[TBL] [Abstract][Full Text] [Related]
7. Non-Small Cell Lung Cancer: Targetable Variants in Concurrent Tissue and Liquid Biopsy Testing in a North Indian Cohort.
Paturu R; Lingaiah R; Kumari N; Singh S; Krishnani N; Srivastava S; Siddiqui SH; Nath A
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3467-3475. PubMed ID: 37898852
[TBL] [Abstract][Full Text] [Related]
8. [Receptor tyrosine kinase- fusions in paediatric spindle cell tumors].
Brenner C; Sanders C; Vokuhl C
Pathologie (Heidelb); 2023 Nov; 44(6):357-365. PubMed ID: 37819532
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase gene rearrangements in epithelial malignancies.
Shaw AT; Hsu PP; Awad MM; Engelman JA
Nat Rev Cancer; 2013 Nov; 13(11):772-87. PubMed ID: 24132104
[TBL] [Abstract][Full Text] [Related]
10. Covalent chemistry on nanostructured substrates enables noninvasive quantification of gene rearrangements in circulating tumor cells.
Dong J; Jan YJ; Cheng J; Zhang RY; Meng M; Smalley M; Chen PJ; Tang X; Tseng P; Bao L; Huang TY; Zhou D; Liu Y; Chai X; Zhang H; Zhou A; Agopian VG; Posadas EM; Shyue JJ; Jonas SJ; Weiss PS; Li M; Zheng G; Yu HH; Zhao M; Tseng HR; Zhu Y
Sci Adv; 2019 Jul; 5(7):eaav9186. PubMed ID: 31392269
[TBL] [Abstract][Full Text] [Related]
11. Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies.
Chang X; Liu Z; Man S; Roys A; Li Z; Zuo D; Wu Y
RSC Adv; 2019 Jun; 9(31):17921-17932. PubMed ID: 35520562
[TBL] [Abstract][Full Text] [Related]
12. Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond.
Khoo C; Rogers TM; Fellowes A; Bell A; Fox S
Transl Lung Cancer Res; 2015 Apr; 4(2):126-41. PubMed ID: 25870795
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive biomarkers in non-small cell lung carcinoma.
Odintsov I; Sholl LM
Pathology; 2024 Mar; 56(2):192-204. PubMed ID: 38199926
[TBL] [Abstract][Full Text] [Related]
14. The association of ROS1 mutation with cancer immunity and its impact on the efficacy of pan-cancer immunotherapy.
Li Y; Zhao H; Huang J; Yan H; Zhao B
J Transl Med; 2024 Apr; 22(1):403. PubMed ID: 38689327
[No Abstract] [Full Text] [Related]
15. Mutational landscape and predictors of survival in head and neck mucosal melanoma.
Lehrich BM; Abiri A; Nguyen TV; Bitner BF; Tong CCL; Kuan EC
Int Forum Allergy Rhinol; 2024 Apr; 14(4):858-861. PubMed ID: 37676479
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B
Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792
[TBL] [Abstract][Full Text] [Related]
17. Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer.
Wan Y; Liu B; Lei H; Zhang B; Wang Y; Huang H; Chen S; Feng Y; Zhu L; Gu Y; Zhang Q; Ma H; Zheng SY
Ann Oncol; 2018 Dec; 29(12):2379-2383. PubMed ID: 30339193
[TBL] [Abstract][Full Text] [Related]
18. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
19. Targeting
Sehgal K; Patell R; Rangachari D; Costa DB
Transl Cancer Res; 2018 Aug; 7(Suppl 7):S779-S786. PubMed ID: 30327756
[No Abstract] [Full Text] [Related]
20. Elevation of tumor mutation burden in ROS1-fusion lung adenocarcinoma resistant to crizotinib: A case report.
Yang T; Xu R; Yan B; Li F; Liu H
Medicine (Baltimore); 2018 Dec; 97(52):e13797. PubMed ID: 30593165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
